To date Parkinson’s disease (PD) is diagnosed clinically and rather late in the course of the disease. There is an urgent need to find an objective, quantifiable biomarker for the diagnosis of this highly prevalent movement disorder. Researchers have now found initial evidence that a blood test to detect the alpha-synuclein protein is a viable, less invasive option to diagnose PD. The study appears in the Journal of Parkinson’s Disease, published by IOS Press, now part of Sage.
After 10 years of game-changing immunotherapies, a cancer conference celebrates — and sees more work to do
BARCELONA, Spain — Ten years ago, a new type of cancer treatment reached the market. It worked by rousing the body’s own immune cells to
September 16, 2024